Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
chrs · stock forecast · 16 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 16 Wall Street analysts in the past 3 months
Buy
16 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$11.00
Consensus
$6.02
+316.6% upside
Low
$1.05
Median: $6 · Last Close: $1.45
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$6.02
316.6% upside
High Target
$11
661.2%
Low Target
$1.05
-27.3%
Current Price
$1.45
as of today
Based on analyst price targets, the CHRS stock price prediction for the next 12 months ranges from $1.05 to $11. The consensus CHRS price forecast of $6.02 implies 316.6% upside from the current price of $1.45.
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.39 | ↓ 3.63% |
1-day model range: $1.36–$1.42. Peak: $1.42 (-3.63%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · CHRS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-09-04 | Maxim Group | Upgrade ↑ | Hold→Buy |
| 2025-04-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-24 | UBS | Maintains | Neutral→Neutral |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-22 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-05 | Baird | Maintains | Outperform→Outperform |
| 2024-12-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-08 | Baird | Maintains | Outperform→Outperform |
| 2024-11-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Coherus Oncology, Inc. (CHRS) stock. Of the recent 81 rating actions, 2 were upgrades and 3 were downgrades. 16 analysts currently cover CHRS.
Analyst Recommendation Trends
CHRS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$73M
↓ 60.5% YoY
Revenue Next Year
$88M
↑ 21.1% YoY
EPS This Year
$-1.01
EPS Next Year
$-0.64
↓ 37.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast CHRS EPS of $-1.01 for the current fiscal year, based on estimates from 2 analysts. The CHRS revenue forecast is $73M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CHRS stock forecast is supported by two independent data sources: analyst consensus ratings from 16 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CHRS price target is $6.02 (+316.6% upside), with an analyst consensus of Buy.
The CHRS short-term stock prediction for tomorrow is $1.39 (-3.63%). The CHRS stock prediction for 2030 projects a range of $0–$0.
Coherus Oncology, Inc. trades on NASDAQ under the ticker CHRS. The CHRS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 81% of covering analysts.
Frequently asked questions
CHRS forecast · 8 questionsAccording to 16 Wall Street analysts, the average 12-month CHRS price target is $6.02, with a high forecast of $11.00 and a low of $1.05. The median price target is shown in the chart above when available. This implies +316.6% potential upside from the current price of $1.45.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.